title: Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.
abstract: We evaluated the activity of CB-183,315 against Clostridium difficile, including strains that are resistant to fluoroquinolones and metronidazole and with elevated MICs to vancomycin as well as other Gram-positive intestinal pathogens. The MICs of CB-183,315 against all C. difficile isolates were ≤ 1 μg/ml. CB-183,315 had greater activity than vancomycin and metronidazole against C. difficile isolates and was more active than the comparators against vancomycin-resistant enterococcus (VRE). CB-183,315 also had excellent activity against methicillin-resistant Staphylococcus aureus (MRSA), other Clostridium spp., and Peptostreptococcus spp.
authors.affiliation: Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA. dsnydman@tuftsmedicalcenter.org
authors.forename: D R
authors.initials: DR
authors.lastname: Snydman
authors.forename: N V
authors.initials: NV
authors.lastname: Jacobus
authors.forename: L A
authors.initials: LA
authors.lastname: McDermott
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects* / Q000472:pathogenicity; D024901:Drug Resistance, Multiple, Bacterial; D016983:Enterococcus / Q000187:drug effects / Q000472:pathogenicity; D007422:Intestines / Q000382:microbiology*; D055666:Lipopeptides / Q000494:pharmacology*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000472:pathogenicity; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010462:Peptostreptococcus / Q000187:drug effects / Q000472:pathogenicity; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D055666:Lipopeptides; D008795:Metronidazole; D014640:Vancomycin